BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 8965951)

  • 1. [The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes].
    Schattenberg AV; van de Wiel-van Kemenade E; Bär BM; Geurts van Kessel AH; van der Maazen RW; de Witte TJ
    Ned Tijdschr Geneeskd; 1996 Oct; 140(42):2087-91. PubMed ID: 8965951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
    Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
    Blair A; Goulden NJ; Libri NA; Oakhill A; Pamphilon DH
    Blood Rev; 2005 Nov; 19(6):289-300. PubMed ID: 16275419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
    Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
    Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation.
    Huang X; Guo N; Ren H; Zhang Y; Gao Z; Lu D
    Chin Med J (Engl); 2003 May; 116(5):736-41. PubMed ID: 12875692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission.
    Vey N; Blaise D; Stoppa AM; Bouabdallah R; Lafage M; Sainty D; Cowen D; Viens P; Lepeu G; Blanc AP
    Bone Marrow Transplant; 1994 Sep; 14(3):383-8. PubMed ID: 7994259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.
    Porter DL; Roth MS; Lee SJ; McGarigle C; Ferrara JL; Antin JH
    Bone Marrow Transplant; 1996 Nov; 18(5):975-80. PubMed ID: 8932854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relapse of acute leukemia after allogeneic bone marrow transplantation].
    Tahara T; Yamazaki T; Abe A; Yamamoto K; Towatari M; Matsuoka A; Matsushita T; Kato H; Toyozumi H; Takeo T
    Rinsho Ketsueki; 1994 Feb; 35(2):120-6. PubMed ID: 8139109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
    Miglino M; Berisso G; Grasso R; Canepa L; Clavio M; Pierri I; Pietrasanta D; Gatto S; Varaldo R; Ballerini F; Verdiani S; Casarino L; DeStefano F; Sessarego M; Dominietto A; Raiola AM; Bregante S; di Grazia C; Gobbi M; Bacigalupo A
    Bone Marrow Transplant; 2002 Nov; 30(9):579-85. PubMed ID: 12407432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.